This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions

This study has been completed.
Information provided by:
Drugs for Neglected Diseases Identifier:
First received: April 14, 2011
Last updated: March 29, 2017
Last verified: April 2011
The present study is designed to assess the impact of concomitant food intake on the relative bioavailability of a single oral fexinidazole tablet administration.

Condition Intervention Phase
PK in Healthy Volunteers Drug: Fexinidazole Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Basic Science
Official Title: Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers

Further study details as provided by Drugs for Neglected Diseases:

Primary Outcome Measures:
  • Plasma concentration measurement of fexinidazole, fexinidazole sulfoxide and sulfone metabolites after a single oral dose of fexinidazole (1200mg) administration and under different food intake conditions

Secondary Outcome Measures:
  • Occurence of AEs
    To assess safety and tolerability of fexinidazole tablets administered as single oral dose under fasting conditions and after two different meals in healthy male volunteers.

Enrollment: 12
Study Start Date: February 2011
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fasting
Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
Drug: Fexinidazole
Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
Experimental: Meal 1: Plumpy Nuts
Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
Drug: Fexinidazole
Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
Experimental: Meal 2: Rice + beans
Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
Drug: Fexinidazole
Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male healthy volunteers 18 to 45 years of age,
  • All subjects to be of sub-Saharan African origins with both parents of sub- Saharan African origins too,
  • Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2) from 18 to 28 kg/m2 at screening,
  • Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study,
  • Provision of written informed consent to participate as shown by a signature on the volunteer consent form,
  • Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study,
  • Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min,
  • Registered with the French Social Security in agreement with the French law on biomedical experimentation.

Exclusion Criteria:

  • Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection,
  • With any clinically significant abnormality following review of pre-study laboratory tests (aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and alkaline phosphatase (ALP) must be within normal ranges), vital signs, full physical examination and Electrocardiogram (ECG),
  • Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health,
  • Who forfeit their freedom by administrative or legal award or who were under guardianship,
  • Unwilling to give their informed consent,
  • Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti- HCV antibodies
  • Who have a history of allergy, intolerance or photosensitivity to any drug,
  • Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,
  • Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol),
  • Who drink more than 8 cups daily of beverage containing caffeine,
  • Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines),
  • Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,
  • Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration,
  • Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study,
  • Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01340157

SGS Aster s.a.s.
Paris, France, 75015
Sponsors and Collaborators
Drugs for Neglected Diseases
Principal Investigator: Lionel Hovsepian, MD SGS Aster
Study Director: Antoine Tarral, MD Drugs for Neglected Diseases Initiative
  More Information

Additional Information:
Responsible Party: Antoine Tarral, MD, Drugs for Neglected Diseases Initiative Identifier: NCT01340157     History of Changes
Other Study ID Numbers: DNDiFEX002
Study First Received: April 14, 2011
Last Updated: March 29, 2017

Keywords provided by Drugs for Neglected Diseases:
Phase I
Bioavailability study
Food effect
Human African Trypanosomiasis processed this record on July 19, 2017